VNDA Vanda Pharmaceuticals Inc.

15.95
-0.15  -1%
Previous Close 16.10
Open 16.05
Price To book 5.44
Market Cap 715489933
Shares 44,858,303
Volume 588,436
Short Ratio 2.68
Av. Daily Volume 602,219

SEC filingsSee all SEC filings

  1. 8-K - Current report 171141740
  2. 8-K - Current report 171083665
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171002758
  4. 8-K - Current report 17999922
  5. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17957441

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 1H 2018.
Tradipitant
Gastroparesis
PK trial initiated with data due 2018.
HETLIOZ (tasimelteon)
Insomnia
Approved May 26, 2016.
Fanapt
Supplemental New Drug Application (sNDA) as a maintenance treatment of schizophrenia in adults.
Approved January 31, 2014.
HETLIOZ (tasimelteon)
Insomnia
Phase 2 data due in 2H 2017.
HETLIOZ (tasimelteon)
Jet Lag Disorder
Phase 3 initiated 4Q 2016. Data due 2018.
HETLIOZ (tasimelteon)
Smith-Magenis Syndrome
Phase 2 data released September 13, 2017 - primary endpoint not met.
Tradipitant
Chronic pruritus in patients with atopic dermatitis

Latest News

  1. ETFs with exposure to Vanda Pharmaceuticals, Inc. : October 17, 2017
  2. Vanda Pharmaceuticals Announces Participation at the Oppenheimer Specialty Pharma Summit Conference
  3. Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US : October 10, 2017
  4. Vanda to Present Tradipitant Phase II Atopic Dermatitis Data at World Congress of Itch
  5. Vanda to Present Scientific Posters at World Sleep 2017
  6. Vanda Pharmaceuticals, Inc. :VNDA-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017
  7. These 3 Biotech Stocks Just Hit 52-Week Highs: Are They Buys?
  8. Is It Too Late To Buy Vanda Pharmaceuticals Inc (VNDA)?
  9. Summit Therapeutics Stock Gets Smoked After IPO Pricing
  10. Vanda Pharma shares decline as goal of itch drug study not reached
  11. Vanda's Tradipitant Improves Itch and Disease Severity in Patients with Atopic Dermatitis
  12. Vanda Pharmaceuticals Announces Participation at September 2017 Investor Conferences
  13. Vanda Pharmaceuticals Announces Participation at the Citi 12th Annual Biotech Conference
  14. Edited Transcript of VNDA earnings conference call or presentation 2-Aug-17 8:30pm GMT
  15. Looking for a Top Momentum Stock? 3 Reasons Why Vanda Pharmaceuticals (VNDA) is a Great Choice
  16. Zacks.com featured highlights Sanderson Farm, Heska Corp, Vanda Pharmaceuticals Lantheus and NVR
  17. 5 Efficient Stocks to Buy for a Healthy Portfolio
  18. Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VNDA-US : August 23, 2017
  19. Vanda Pharmaceuticals, Inc. – Value Analysis (NASDAQ:VNDA) : August 21, 2017